Pulmonx Corp (LUNG) — Titan Protect Analysis

LUNG

Pulmonx Corp

Healthcare · ·

$1.53

Data: 2026-06-03

✓ ETHICAL PASS

NONE MOAT

LIMITED

Data Confidence: 0.0%

Key Metrics

How this company measures up on the fundamentals that matter

Market Cap

$66M

Total market value of the company

Trailing P/E

N/A

Forward P/E

-1.49

Based on estimated future earnings — lower means cheaper

Rev Growth

-8.7%

Year-over-year revenue change

Profit Margin

-60.1%

How much profit the company keeps from each dollar of revenue

ROE

-86.2%

Return on equity — how efficiently it uses shareholder money

Analyst Target

$3.00

+96% from current price — median analyst estimate

Recommendation

BUY

Consensus view from 5 analysts covering this stock

About Pulmonx Corp

Pulmonx Corporation, a commercial-stage medical technology company that provides a minimally invasive treatment for patients with severe emphysema, a form of chronic obstructive pulmonary disease. It offers Zephyr Endobronchial Valve; and Chartis Pulmonary Assessment System, a balloon catheter and console system with flow and pressure sensors that are used to assess the presence of collateral ventilation. The company also offers LungTraX Platform, a cloud-based quantitative computed tomography a

https://pulmonx.com

Country: United States Employees: 296 Industry: Medical Devices

Ethical Screening

Five compliance checks based on AAOIFI standards — all must pass for ethical clearance

Business Activity

PASS

Core business does not involve prohibited activities

Debt Ratio

0.0% PENDING

Debt must be below 33% of total assets

Cash Ratio

0.0% PENDING

Interest-bearing cash below 33% of assets

Receivables

0.0% PENDING

Receivables below 49% of assets

Revenue Purity

0.0% PENDING

Non-compliant revenue below 5% — any excess requires purification

Quantitative Intelligence

Statistical analysis of price behaviour, risk, and market regime — independent of fundamental data

Regime

MARKUP

Price trending up with increasing momentum

Sharpe Ratio

-0.393

Returns do not compensate for the risk — negative edge

Kelly Fraction

-0.0682

No positive edge detected — the data suggests staying out

Calmar Ratio

-0.599

Drawdown risk outweighs the returns — higher risk profile

Annual Return

-52.3%

Historical annualised return based on price data

Max Drawdown

-87.3%

Largest peak-to-trough decline — the worst it has been

HMM State

SIDEWAYS

Price consolidating — no clear directional bias

Days in State

How long the current regime has persisted — longer means more stable

Market Data

Trading characteristics and market positioning

Beta

0.18

Very low correlation to market moves

52W High

$3.88

61% below the year high

52W Low

$1.13

35% above the year low

Avg Volume

551,049

Average daily shares traded — higher means easier to buy and sell

Short Ratio

5.1

Days it would take all short sellers to cover — higher means more crowded

Short % Float

N/A

Div Yield

N/A

Annual dividend as a percentage of the share price

EPS (TTM)

$-1.30

Earnings per share over the last 12 months

Financial Health

Balance sheet strength and cash generation — the foundation of long-term value

Debt/Equity

123.02

Heavy leverage — higher financial risk if revenues decline

Current Ratio

N/A

Quick Ratio

N/A

Like current ratio but excludes inventory — stricter test

Gross Margin

75.5%

Revenue left after cost of goods — higher means pricing power

Operating Margin

-62.9%

Profit from core operations before interest and tax

Free Cash Flow

$-8,362,750

Negative — the business is spending more than it generates

Revenue (TTM)

$89M

Total revenue over the last 12 months

Net Income

$-53,209,000

Loss-making — spending exceeds revenue after all costs

Analyst Coverage

Analysts

Target High

$5.00

Target Median

$3.00

Target Low

$2.50

Explore the Ethical Screener View Track Record

Data sourced from public filings and market feeds. Not financial advice. Updated: 2026-06-03

Before you go